anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a retinal progenitor cell generated by separating and inducing as well as a composition including the cell. The cell is transplanted to a host, so that integration rate and oncogenicity of the retina are greatly improved. The invention further provides a method of preparing the retinal progenitor cell by restraining a classical Wnt signal channel as well as a method of preparing the retinal progenitor cell suitable for transplanting. The invention further provides a composition consisting: (a), a Tcf1 protein, (b), a beta-catenin protein, and (c), a Sox2 protein as well as an application of the composition in screening a drug for lowering cell oncogenicity generated by inducing. The invention further provides a method of screening the drug for lowering cell oncogenicity generated by inducing. The invention opens up a novel way for cell treatment.
<P>PROBLEM TO BE SOLVED: To provide a high intensity radiopaque contrast agent.  <P>SOLUTION: This contrast agent can be applied on or incorporated in a bulk material and after that, the material can be used for the preparation of a radiopaque medical device. The main action by its chemical properties is to comparatively heighten the radiopaque concentrations per unit weight of the radiopaque element or substance, and the secondary action is to enable selective placement of the radiopaque element. Thus, the radiopacity of the device can be enhanced with reduced amounts of the radiopaque substance. The radiopaque contrast agent can be produced in various forms such as a dendrimer and/or be incorporated as the end groups of polymeric chain. Further, biological and/or medicinal substances can be incorporated in combination of the agent.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The study is an open-label phase 2 study of entospletinib in younger and older AML patients with NPM1+/FLT3ITD-AML. It includes patients age ≥18 years who are able and willing to receive 7 + 3 intensive chemotherapy. Entospletinib is administered daily with IV daunorubicin (days 1-3 for Cycle 1) and cytarabine (days 1-7 for Cycle 1). If a second induction is required, it is given with IV daunorubicin (days 1-2 for Cycle 2) and cytarabine (days 1-5 for Cycle 2).
NEW MATERIAL:Crystal 2-O-alpha-D-glucopyranosyl-L-ascorbic acid. Main diffraction angles (2theta) are 10.3 deg., 14.8 deg., 16.2 deg., 18.4 deg. and 24.5 deg. in powder X-ray diffraction using CuKalpha ray. USE:An agent for alleviating sensitive diseases and a cosmetic. PREPARATION:A solution containing L-ascorbic acid and an alpha-glucosyl saccharide compound is treated with transglycosylase or transglycosylase and glucoamylase to form a solution containing 2-O-alpha-D-glucopyranosyl-L-ascorbic acid, which is purified by chromatography selected from ion exchange chromatography and gel filtration chromatography and crystal is precipitated from a concentrated supersaturated solution of 2-O-alpha-D-glucopyranosyl-L-ascorbic acid.
OBJECTIVE: Sepsis and sepsis-associated organ failure are devastating conditions for which there are no effective therapeutic agent. Several studies have demonstrated the significance of ferroptosis in sepsis. The study aimed to identify ferroptosis-related genes (FRGs) in sepsis, providing potential therapeutic targets.
METHODS: The weighted gene co-expression network analysis (WGCNA) was utilized to screen sepsis-associated genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to explore gene functions. Three machine learning methods were employed to identify sepsis-related hub genes. Survival and multivariate Cox regression analysis allowed further screening for the key gene RRM2 associated with prognosis. The immune infiltration analysis of the screened sepsis key genes was performed. Additionally, a cecum ligation and puncture (CLP)-induced mouse sepsis model was constructed to validate the expression of key gene in the sepsis.
RESULTS: Six sepsis-associated differentially expressed FRGs (RRM2, RPL7A, HNRNPA1, PEBP1, MYL8B and TXNIP) were screened by WGCNA and three machine learning methods analysis. Survival analysis and multivariate Cox regression analysis showed that RRM2 was a key gene in sepsis and an independent prognostic factor associated with clinicopathological and molecular features of sepsis. Immune cell infiltration analysis demonstrated that RRM2 had a connection to various immune cells, such as CD4 T cells and neutrophils. Furthermore, animal experiment demonstrated that RRM2 was highly expressed in CLP-induced septic mice, and the use of Fer-1 significantly inhibited RRM2 expression, inhibited serum inflammatory factor TNF-α, IL-6 and IL-1β expression, ameliorated intestinal injury and improved survival in septic mice.
CONCLUSION: RRM2 plays an important role in sepsis and may contribute to sepsis through the ferroptosis pathway. This study provides potential therapeutic targets for sepsis.
A specific particle size distribution of feldspar is employed as both a cleaning and a polishing agent for teeth. It consists initially of a powder that, preferably at the time of use, is mixed with a moistener and becomes a paste to be used by the dentist or dental hygienist. It can be combined with a humectant but in smaller proportions than heretofore. It can be used with or without a dental caries-reducing amount of a fluoride anticariogenic agent, either stannous or sodium fluoride, and is more effective than prior materials though mixed with much smaller quantities. It can be supplied in a sectional kit wherein the initially-separated wet and dry ingredients can be joined at the time of use. It can be used as a self-administered prophylactic paste for mass treatment applications.
Stroke survivors often experience loss of motor control and impaired function. Immediately after stroke, there is a time-limited window of heightened plasticity during which the greatest gains in recovery occur. Therefore, early intensive sensorimotor rehabilitation post-stroke is critical in improving functional outcomes and minimizing disability. However, acute stroke survivors often receive little active training to improve mobility during their hospital stay and they are left alone during most of the day. Especially for those acute patients with no voluntary motor output, active motor training might be even less, partly due to a lack of rehabilitation protocols to detect potential motor recovering signals sensitively and facilitate neuroplastic changes. To address this unmet clinical need, this project will develop a novel wearable rehabilitation robot suitable for in-bed acute stage rehabilitation with guided motor relearning, passive and active motor-sensory rehabilitation early in the acute stage post-stroke including patients who are paralyzed with no motor output. The early acute stroke rehabilitation device will be evaluated in this clinical trial.
Symptoms of ocular surface discomfort or dry eye disease for at least 3 months, supported by clinical exam findings. Reported quality of life is not effected by ocular pain.
NEW MATERIAL:A compound of formula. USE:Dyes, pigments and intermediates thereof. PREPARATION:The objective compound can be prepared by the reduction, in the presence of an alkali such as KOH, NaOH or Na2CO3 using a reducing agent such as sodium dithionate, of 2-benzylamino-5,8-dihydroxynaphthoquinone in water, alcohol, water-alcohol mixed solution or Zn-contg. ag. HCl, pref. under an anaerobic condition at room temperature-reflux temperature for 1-5hr.
OBJECTIVE: Cervical spondylotic myelopathy (CSM) stands as the most prevalent form of spinal cord injury, frequently prompting various changes in both the brain and spinal cord. However, the precise nature of these changes within the brains and spinal cords of CSM patients experiencing hand clumsiness (HCL) symptoms has remained elusive. The authors aimed to scrutinize these alterations and explore potential links between these changes and the onset of HCL symptoms.
METHODS: Using the modified Japanese Orthopaedic Association (mJOA) scale, the authors classified CSM patients into two groups: those without HCL and those with HCL. The authors performed voxel-wise z-score transformation amplitude of low-frequency fluctuations (zALFF) and resting-state functional connectivity (FC) evaluations in the brain. Additionally, they used the Spinal Cord Toolbox to calculate the fractional anisotropy (FA) of spinal cord tracts. The analysis also encompassed an examination of the correlation of these measures with improvements in mJOA scores.
RESULTS: Significant disparities in zALFF values surfaced in the right calcarine, right cuneus, right precuneus, right middle occipital gyrus (MOG), right superior occipital gyrus (SOG), and right superior parietal gyrus (SPG) between healthy controls (HC), patients without HCL, and patients with HCL, primarily within the visual cortex. In the patient group, patients with HCL displayed reduced FC between the right calcarine, right MOG, right SOG, right SPG, right SFG, bilateral MFG, and left median cingulate and paracingulate gyri when compared with patients without HCL. Moreover, significant differences in FA values of the corticospinal tract (CST) and reticulospinal tract (REST) at the C2 level emerged among HC, patients without HCL, and patients with HCL. Notably, zALFF, FC, and FA values in specific brain regions and spinal cord tracts exhibited correlations with mJOA upper-extremity scores. Additionally, FA values of the CST and REST correlated with zALFF values in the right calcarine, right MOG, right SOG, and right SPG.
CONCLUSIONS: Alterations within brain regions associated with the visual cortex, the fronto-parietal-occipital attention network, and spinal cord pathways appear to play a substantial role in the emergence and progression of HCL symptoms. Furthermore, the existence of a potential connection between the spinal cord and the brain suggests that this link might be related to the clinical symptoms of CSM.
At the discharge, the hospital pharmacist will complete the medication reconciliation and assess the patient's medications. All patients enrolled will undergo three interventions in order to improve medication adherence: counseling, pill counts and self-questionnaire. The adherence plan concerns 6 classes of drugs recommended by the European Society of Cardiology in acute myocardial infarction. The adherence plan is performed by the community pharmacists. The hospital pharmacist will complete the discharge care form for the community pharmacist who has in charge the patient. Each patient will be scheduled for the first meeting with his community pharmacist within one month from the hospital discharge; afterward the adherence plan will be submitted every 3 months.
Fusion protein comprises a thioredoxin and human serum albumin. The thioredoxin comprises a protein comprising the amino acid sequence shown in SEQ. ID. No.1, or the like, the human serum albumin comprises a protein comprising the amino acid sequence shown in SEQ. ID. No. 2, or the like. The fusion protein of the invention allows the activity of thioredoxin to be maintained over a long period of time. It is thus possible to provide a protein preparation that is stable over long periods of time.
PURPOSE OF REVIEW: Stress urinary incontinence (SUI) is a common condition for which women often opt for surgical management. Synthetic midurethral slings (MUS) have been the dominant treatment for decades. Single-incision slings (SIS) have been introduced to lower the morbidity associated with trocar passage during MUS placement. Urethral bulking has been used less frequently owing to its lower cure rates. New data have recently emerged in support of single-incision slings (SIS) and urethral bulking with Bulkamid polyacrylamide hydrogel (PAHG).
RECENT FINDINGS: Several studies with a follow-up ≥10 years have shown stable efficacy and complication rates of retropubic (RMUS) and transobturator (TMUS) midurethral slings over time. SIS products show equivalent efficacy to traditional TMUS and RMUS at up to 3 years of follow-up and can be placed under local anesthesia. While urethral bulking with PAHG results in lower cure rates compared to slings, satisfaction rates are high and responders have sustained improvement at 7 years follow-up.
SUMMARY: All three types of available slings, TMUS, RMUS, and SIS, are now considered appropriate surgical options for the treatment of SUI. Although the absence of comparative data precludes a formal recommendation for one injectable over another, urethral bulking with PAHG has favorable long-term results and an excellent safety profile.
The detection of gallium in biological samples is required due to its role in the diagnosis of tumor and for possible treatment of malignancies. However, the use of purely instrumental techniques is unsuitable for detection of low levels of gallium in biological matrices. New protein conjugates have been synthesized based on 4-(2-pyridylazo) ligands. The conjugates detect gallium in biological matrices using a non antibody-based sandwich assay format. The recovery level is between 97-101.3 with a relative standard deviation of less than 5%. The assay results in a detection limit of 5x10-8 M and a remarkable selectivity for gallium(III) relative to other metals investigated. The new method provides adequate accuracy for gallium applicable for animal physiology and clinical toxicology.
FIELD: cosmetology and medical equipment. SUBSTANCE: composition may be used as a base for production of cosmetic and medical preparations, food additive, and as hydrophilic lubricants, coolants, and as an intermediate product for introduction and uniform distribution of lipophilous substances in volume of other substances. Composition is a stable aqueous composition of lipophilous substance, preferably, oils, including nondestructive polysaccharide without steric or other obstacles for free rotation of monomeric links in polymeric chain around valent chemical bonds C-O-C connecting them. The composition may additionally contain vitamins, flavors, metal salts and other additives. Method of composition preparation includes dissolving of polysaccharide in aqueous dispersing medium at heating, introduction lipophilous substance in solution at continuous mixing, and heat treatment of prepared mixture under conditions of sufficient turbulence. Method is conducted in soft thermal conditions: at temperatures lower than that at the beginning of destruction and desolvation of polysaccharide. EFFECT: higher efficiency. 25 cl, 25 tbl
The safety and efficacy of VISIPAQUE have been established in pediatric patients down to birth for angiocardiography, cerebral arteriography, visceral arteriography, CT imaging of the head and body, and excretory urography. The safety and efficacy of VISIPAQUE have also been established in pediatric patients 12 years and older for intra-arterial digital subtraction angiography, peripheral arteriography, peripheral venography and CCTA. Use of VISIPAQUE is supported by evidence from adequate and well controlled studies of VISIPAQUE in adults and additional safety data obtained in 459 pediatric patients. In general, the types of adverse reactions reported are similar to those of adults. A higher number of adverse events in patients less than 1 year of age compared to older patients were observed in a study of VISIPAQUE [see Adverse Events (6.3)]. The elimination of VISIPAQUE is slower in this age group [see Clinical Pharmacology (12.3)].

Thyroid function tests indicative of thyroid dysfunction, characterized by hypothyroidism or transient thyroid suppression have been reported following iodinated contrast media administration in pediatric patients, including term and preterm neonates. Some patients were treated for hypothyroidism. After exposure to iodinated contrast media, individualize thyroid function monitoring in pediatric patients 0 to 3 years of age based on underlying risk factors, especially in term and preterm neonates [see Warnings and Precautions (5.8) and Adverse Reactions (6.2)].

Pediatric patients at higher risk of experiencing an adverse reaction during and after administration of any contrast agent may include those with asthma, hypersensitivity to other medication and/or allergens, cyanotic and acyanotic heart disease, congestive heart failure, or a serum creatinine greater than 1.5 mg/dL. Pediatric patients with immature renal function or dehydration may be at increased risk for adverse events due to slower elimination of iodinated contrast agents [see Clinical Pharmacology (12.3)].
For cloud-based computer assisted detection, hierarchal detection is used, allowing detection on data at progressively greater resolutions. Detected locations at coarser resolutions are used to limit the data transmitted at greater resolutions. Data is only transmitted for neighborhoods around the previously detected locations. Subsequent detection using higher resolution data refines the locations, but only for regions associated with previous detection. By limiting the number and/or size of regions provided at greater resolutions based on the previous detection, the progressive transmission avoids transmission of some data. Additionally, or alternatively, lossy compression may be used without or with minimal reduction in detection sensitivity.
One challenging complication to stroke is the development of hemiplegic shoulder pain, which is reported in approximately 30% of the stroke population. Treatment strategies recommended in the Swedish National Guidelines for Stroke Care (NBHW) include use of assistive devices for arm support and treatment with transcutaneous electric nerve stimulation (TENS), which may impact on both pain and muscle tone. In an innovative approach, a full body suit with multiple electrodes for provision off electrical stimulation has been developed by a small Swedish med-tech company. The suit ( EXOPULSE Mollii suit) is currently used for treatment of disabling spasticity and to improve motor function in persons living with effects of central nervous system disease or injury. The theoretical background of the EXOPULSE Mollii-method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle. Thus, the application of EXOPULSE Mollii aims at stimulating a muscle, e.g. the anterior tibial muscle of the lower leg in order to reduce reflex mediated over-activity, i.e. spasticity, in calf muscles by inducing reciprocal inhibition. Studies on the effects on spasticity and perceived usability of the suit in a stroke population have recently been completed by our study group at the Department of Rehabilitation Medicine Stockholm at Danderyd Hospital (dnr 2017/935-31) and preliminary analyses indicate that spasticity may be reduced by use of the suit.

Based on the theoretical and practical background outlined above, this study will explore the potential value of the Mollii-method in the management of post stroke shoulder pain. The overall aim of this study is to test and further develop the Mollii-suit for its ability to reduce hemiplegic shoulder pain. The specific aims are 1) to compare the effect of different stimulation modes for shoulder pain reduction 2) to explore which patients will respond best to these.
The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The identification threshold of normal lung density and LAA is set at -960 HU. The cut-off level between high or low LAA% is the mean + 2SD of LAA% of the asymptomatic non-COPD smokers.
BACKGROUND AND OBJECTIVES: The aim of this study is to explore the long-term prognostic risk factors associated with patients diagnosed with retroperitoneal paraganglioma (RPGL) and examine their clinical and pathological characteristics.
METHODS: Expressions of biomarkers were identified using immunohistochemistry (IHC) and case databases were retrospectively searched. Survival analysis was performed using Kaplan-Meier and Cox risk regression to identify the factors that influence the postoperative progression-free survival of patients with RPGL.
RESULTS: A total of 105 patients, most of whom had tumors situated in the paraaortic region, and whose average tumor size was 8.6 cm, were enrolled in this study. The average follow-up duration was 51 months, with a mortality rate of 19% and a recurrence and metastasis rate of 41.9%. Tumors were assessed using the modified Grading system for Adrenal Pheochromocytoma and Paraganglioma (GAPP), and SDHB, S-100, and Ki-67 were stained using IHC in all cases. Out of the total cases examined, negative in SDHB expression were observed in 18.1% of cases, S-100 expression was negative in 36.2% of cases, and endovascular tumor enboluswas present in approximately 25.7% of cases. The results of the univariate analysis indicated that several factors significantly influenced the progression-free survival of patients with PGL as follow: maximum tumor diameter (>5.5 cm), tumor morphological features, tumor grading (modified GAPP score > 6), SDHB negative, S-100 negative, and expression of proliferation index Ki-67 (>3%) (X2 = 4.217-27.420, p < 0.05). The results of the multivariate analysis indicated that negative of S-100 (p = 0.021) and SDHB (p = 0.038), as well as intravascular tumor thrombus (p = 0.047) expression were independent risk factors for progression-free survival in patients.
CONCLUSION: RPGL is characterized by diverse biological features and an elevated susceptibility to both recurrence and metastasis. Both SDHB and S-100 can be employed as traditional IHC indicators to predict the metastatic risk of PGL, whereas the tumor histomorphology-endovascular tumor enbolus assists in determining the metastasis risk of RPGL.
Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (\< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
The treatment comprises oral administration of a compn. contg. a pharm. acceptable carrier and an acid with vitamin A activity, selected from vitamin A acid, vitamin A2 acid, alpha-vitamin A acid, gamma-vitamin A acid, 13-cis-vitamin A acid and 5,6-epoxy-vitamin A acid, or a pharm. acceptable salt, alkyl ester or amide of these acids. Daily dose of the vitamin A acid is 10-300 mg.
ABSTRACT OF THE DISCLOSURE   A noval pharmaceutical composition for implantation in a natural, pathological or artificial cavity in body tissue and which includes an antibiotic which is slowly released from the composition upon implantation, is provided herein.  The pharmaceutical composition comprises CaSO4, e.g. Plaster of Paris or gypsum, and at least one antibiotic substance,e.g. fusidic acid or gentamycin or their respective pharmaceutical-ly-acceptable salts, selected for its ability to be slowly released from CaSO4 and to maintain antibiotically effective concentrations in fluid in the cavity for a period of up to several weeks.  The preparation of the composition comprises forming a slurry of CaSO4,e.g. calcium sulphate hemihydrate, gypsum or Plaster of Paris, with the desired aforesaid anti-bacterial substance or substances and a suitable amount of sterile water, optionally adding specified auxiliary agent(s), and allowing the slurry obtained to set in moulds, or in situ.